{"success":true,"data":{"pressRelease":{"id":"161769","rtpr_id":"nPn2HhNSWa-20261006","ticker":"VST","exchange":"","all_tickers":["VST"],"title":"Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List","author":"PR Newswire","published_at":"2026-10-06T12:00:18.941Z","article_body":"Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List\nPR Newswire\n\nVANCOUVER, BC, Oct. 6, 2026\n\nVST places No. 58 overall with 497% three-year revenue growth; portfolio spans\nU.S. healthcare infrastructure, peptide drug delivery and pet health\n\nVANCOUVER, BC, Oct. 6, 2026 /PRNewswire/ -- Victory Square Technologies Inc.\n(\"Victory Square\", \"VST\" or the \"Company\") (CSE: VST) (OTCQX: VSQTF) (FWB:\n6F6), a publicly traded venture builder, is pleased to announce that it has\nranked No. 58 overall on The Globe and Mail's 2026 Report on Business ranking\nof Canada's Top Growing Companies, achieving 497% revenue growth from 2022 to\n2025.\n\nVictory Square also holds the second-highest position among the 24 publicly\ntraded companies included in the ranking, based on the Company's review of the\npublished list filtered by publicly traded status.\n\nThe 497% increase represents nearly a sixfold expansion in revenue over the\nmeasurement period. The recognition comes as Victory Square continues to scale\nits consolidated operations while developing businesses across healthcare\ninfrastructure, biotechnology and pet health.\n\n\"Behind this recognition are years of building, teams that kept executing and\nshareholders who supported us along the way,\" said Shafin Diamond Tejani, CEO\nof Victory Square Technologies. \"Placing second among the publicly traded\ncompanies on this list is a proud moment for everyone involved. It reflects\nmeaningful progress in turning the businesses we help build into operations\nwith real commercial scale.\"\n\nContinued growth beyond the ranking period\n\nThe ranking measures revenue growth through 2025. Victory Square's previously\nannounced results show continued expansion in the first half of 2026:\n\n * Consolidated revenue of $53.0 million, compared with $9.9 million in the first\nhalf of 2025, an increase of approximately 434%.\n * Consolidated gross profit of $10.5 million, compared with $3.4 million in the\ncorresponding period.\n * Consolidated cash of $20.2 million and working capital of $34.5 million as at\nJune 30, 2026.\nFirst-half consolidated revenue growth was primarily attributable to Hydreight\nTechnologies Inc., Victory Square's largest operating subsidiary.\n All financial amounts are in Canadian dollars. Readers should review the\n Company's financial statements and Management's Discussion and Analysis on\n SEDAR+ for additional information.\n\nWhat investors gain exposure to through VST\n\nVictory Square provides public-market investors with exposure to operating and\ndevelopment-stage technology businesses through a single publicly traded\ncompany. Its approach combines investment capital with operational support,\nstrategic guidance and industry relationships to help businesses develop and\nscale.\n\nCurrent areas of focus include:\n\nHydreight Technologies — U.S. healthcare infrastructure\n\nHydreight (TSXV: NURS) operates a digital health infrastructure platform\nsupporting healthcare providers, businesses and direct-to-consumer healthcare\nbrands across all 50 U.S. states. Its platform brings together technology,\nphysician coverage, pharmacy relationships and compliance infrastructure.\nHydreight is the principal driver of Victory Square's consolidated revenue.\n\nInsu Therapeutics — Peptide drug delivery\n\nInsu is developing technology designed to deliver peptide-based medicines\nthrough the inner cheek, known as buccal delivery. Its research includes\nevaluating the delivery of existing therapies such as semaglutide through an\nalternative route of administration. Insu remains a development-stage\nbiotechnology business; clinical validation and applicable regulatory\napprovals are required before commercialization.\n\nPawsible Ventures — Building pet-health businesses\n\nPawsible is a pet-health venture platform supporting founders across\nveterinary technology and animal wellness. In April 2026, it announced its\ninaugural cohort of eight companies, selected from several hundred applicants\nglobally. The cohort spans veterinary infrastructure, diagnostics, AI-enabled\ncare, preventative health and consumer wellness, giving Pawsible a concrete\nstarting point for applying Victory Square's venture-building approach to\ncompanion-animal health.\n\nThese businesses represent different stages of development. Hydreight provides\nestablished commercial operations, while Insu and Pawsible offer exposure to\nearlier-stage opportunities with distinct development and execution risks.\n\n\"Our model gives investors a way to participate in businesses they might\notherwise encounter only through private markets,\" added Tejani. \"We work\nalongside founders and management teams to help those businesses move forward.\nOur priorities are to support execution, allocate capital carefully and\ntranslate portfolio progress into long-term value for VST shareholders.\"\n\nMeet the portfolio: October 8 investor webinar\n\nVictory Square invites existing shareholders and prospective investors to its\nCorporate and Portfolio Update on Thursday, October 8, 2026, at 2:00 p.m.\nPacific Time.\n\nThe webinar will include a closer look at Hydreight, Insu Therapeutics and\nPawsible Ventures, alongside other public and private holdings. Management\nwill discuss net asset value, capital allocation and how progress across the\nportfolio can translate into value for VST shareholders.\n\nThe event will include a live shareholder Q&A.\n\nRegister for the webinar\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=2226286490&u=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2FWN_5XBn7yeITRqjdQwagJcWKQ&a=Register+for+the+webinar)\n\nOn behalf of the Board of Directors\n\nShafin Diamond Tejani\nChairman & Chief Executive Officer\nVictory Square Technologies Inc.\n\nAbout Canada's Top Growing Companies\n\nCanada's Top Growing Companies is an editorial ranking published by The Globe\nand Mail's Report on Business magazine. Launched in 2019, the voluntary\nprogram ranks qualifying Canadian businesses based on three-year revenue\ngrowth following an application and review process.\n\nThe 2026 ranking is available in the October issue of Report on Business\nmagazine and\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=3707409027&u=https%3A%2F%2Fwww.theglobeandmail.com%2Fbusiness%2Frob-magazine%2Ftop-growing-companies%2Farticle-ranking-canadas-top-growing-companies-of-2026%2F&a=%C2%A0)\nonline at The Globe and Mail\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=4184079136&u=https%3A%2F%2Fwww.theglobeandmail.com%2Fbusiness%2Frob-magazine%2Ftop-growing-companies%2Farticle-ranking-canadas-top-growing-companies-of-2026%2F&a=online+at+The+Globe+and+Mail)\n.\n\nAbout Victory Square Technologies Inc.\n\nVictory Square builds, acquires and invests in technology companies, providing\ncapital, strategic leadership and operational support to help them develop and\nscale. Its portfolio includes operating and development-stage businesses\nacross healthcare infrastructure, digital health, artificial intelligence, pet\nhealth and other emerging technology sectors.\n\nHeadquartered in Vancouver, Canada, Victory Square trades on the Canadian\nSecurities Exchange, the OTCQX market and the Frankfurt Stock Exchange.\n\nFor more information, visit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=2138118496&u=https%3A%2F%2Fvictorysquare.com%2F&a=%C2%A0)\nwww.victorysquare.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=2242282608&u=https%3A%2F%2Fvictorysquare.com%2F&a=www.victorysquare.com)\n.\n\nForward-Looking Information\n\nThis news release contains forward-looking information within the meaning of\napplicable securities laws, including statements concerning Victory Square's\nbusiness strategy, portfolio development, capital allocation, potential\nshareholder value, Insu Therapeutics' drug-delivery technology and potential\ncommercialization, Pawsible Ventures' development opportunities, and the\ntiming and content of the planned investor webinar.\n\nSuch information is based on management's current expectations and\nassumptions, including the availability of capital, demand for portfolio\ncompanies' products and services, successful research and development, receipt\nof applicable regulatory approvals and the ability to execute business plans.\nActual results may differ materially due to risks including market and\neconomic conditions, financing requirements, competition, regulatory changes,\nclinical and technological uncertainty, and operational execution. Additional\nrisks are described in the Company's public filings on SEDAR+.\n\nHistorical revenue growth and inclusion in an editorial ranking do not\nguarantee future operating results or investment returns. Readers should not\nplace undue reliance on forward-looking information. The Company undertakes no\nobligation to update such information except as required by applicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/victory-square-technologies-ranks-no-2-among-publicly-traded-companies-on-the-globe-and-mails-2026-canadas-top-growing-companies-list-302899250.html\n(https://www.prnewswire.com/news-releases/victory-square-technologies-ranks-no-2-among-publicly-traded-companies-on-the-globe-and-mails-2026-canadas-top-growing-companies-list-302899250.html)\n\nSOURCE Victory Square Technologies Inc\n\n\n\nir@victorysquare.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1830374/Victory-Square-Technologies-Inc-Victory-Square-Technologies-Rank.jpg?id=OA2988986\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2HhNSWa-20261006","title":"Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List","author":"PR Newswire","ticker":"VST","created":"2026-10-06T12:00:18.941Z","tickers":["VST"],"exchange":"","article_body":"Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List\nPR Newswire\n\nVANCOUVER, BC, Oct. 6, 2026\n\nVST places No. 58 overall with 497% three-year revenue growth; portfolio spans\nU.S. healthcare infrastructure, peptide drug delivery and pet health\n\nVANCOUVER, BC, Oct. 6, 2026 /PRNewswire/ -- Victory Square Technologies Inc.\n(\"Victory Square\", \"VST\" or the \"Company\") (CSE: VST) (OTCQX: VSQTF) (FWB:\n6F6), a publicly traded venture builder, is pleased to announce that it has\nranked No. 58 overall on The Globe and Mail's 2026 Report on Business ranking\nof Canada's Top Growing Companies, achieving 497% revenue growth from 2022 to\n2025.\n\nVictory Square also holds the second-highest position among the 24 publicly\ntraded companies included in the ranking, based on the Company's review of the\npublished list filtered by publicly traded status.\n\nThe 497% increase represents nearly a sixfold expansion in revenue over the\nmeasurement period. The recognition comes as Victory Square continues to scale\nits consolidated operations while developing businesses across healthcare\ninfrastructure, biotechnology and pet health.\n\n\"Behind this recognition are years of building, teams that kept executing and\nshareholders who supported us along the way,\" said Shafin Diamond Tejani, CEO\nof Victory Square Technologies. \"Placing second among the publicly traded\ncompanies on this list is a proud moment for everyone involved. It reflects\nmeaningful progress in turning the businesses we help build into operations\nwith real commercial scale.\"\n\nContinued growth beyond the ranking period\n\nThe ranking measures revenue growth through 2025. Victory Square's previously\nannounced results show continued expansion in the first half of 2026:\n\n * Consolidated revenue of $53.0 million, compared with $9.9 million in the first\nhalf of 2025, an increase of approximately 434%.\n * Consolidated gross profit of $10.5 million, compared with $3.4 million in the\ncorresponding period.\n * Consolidated cash of $20.2 million and working capital of $34.5 million as at\nJune 30, 2026.\nFirst-half consolidated revenue growth was primarily attributable to Hydreight\nTechnologies Inc., Victory Square's largest operating subsidiary.\n All financial amounts are in Canadian dollars. Readers should review the\n Company's financial statements and Management's Discussion and Analysis on\n SEDAR+ for additional information.\n\nWhat investors gain exposure to through VST\n\nVictory Square provides public-market investors with exposure to operating and\ndevelopment-stage technology businesses through a single publicly traded\ncompany. Its approach combines investment capital with operational support,\nstrategic guidance and industry relationships to help businesses develop and\nscale.\n\nCurrent areas of focus include:\n\nHydreight Technologies — U.S. healthcare infrastructure\n\nHydreight (TSXV: NURS) operates a digital health infrastructure platform\nsupporting healthcare providers, businesses and direct-to-consumer healthcare\nbrands across all 50 U.S. states. Its platform brings together technology,\nphysician coverage, pharmacy relationships and compliance infrastructure.\nHydreight is the principal driver of Victory Square's consolidated revenue.\n\nInsu Therapeutics — Peptide drug delivery\n\nInsu is developing technology designed to deliver peptide-based medicines\nthrough the inner cheek, known as buccal delivery. Its research includes\nevaluating the delivery of existing therapies such as semaglutide through an\nalternative route of administration. Insu remains a development-stage\nbiotechnology business; clinical validation and applicable regulatory\napprovals are required before commercialization.\n\nPawsible Ventures — Building pet-health businesses\n\nPawsible is a pet-health venture platform supporting founders across\nveterinary technology and animal wellness. In April 2026, it announced its\ninaugural cohort of eight companies, selected from several hundred applicants\nglobally. The cohort spans veterinary infrastructure, diagnostics, AI-enabled\ncare, preventative health and consumer wellness, giving Pawsible a concrete\nstarting point for applying Victory Square's venture-building approach to\ncompanion-animal health.\n\nThese businesses represent different stages of development. Hydreight provides\nestablished commercial operations, while Insu and Pawsible offer exposure to\nearlier-stage opportunities with distinct development and execution risks.\n\n\"Our model gives investors a way to participate in businesses they might\notherwise encounter only through private markets,\" added Tejani. \"We work\nalongside founders and management teams to help those businesses move forward.\nOur priorities are to support execution, allocate capital carefully and\ntranslate portfolio progress into long-term value for VST shareholders.\"\n\nMeet the portfolio: October 8 investor webinar\n\nVictory Square invites existing shareholders and prospective investors to its\nCorporate and Portfolio Update on Thursday, October 8, 2026, at 2:00 p.m.\nPacific Time.\n\nThe webinar will include a closer look at Hydreight, Insu Therapeutics and\nPawsible Ventures, alongside other public and private holdings. Management\nwill discuss net asset value, capital allocation and how progress across the\nportfolio can translate into value for VST shareholders.\n\nThe event will include a live shareholder Q&A.\n\nRegister for the webinar\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=2226286490&u=https%3A%2F%2Fus06web.zoom.us%2Fwebinar%2Fregister%2FWN_5XBn7yeITRqjdQwagJcWKQ&a=Register+for+the+webinar)\n\nOn behalf of the Board of Directors\n\nShafin Diamond Tejani\nChairman & Chief Executive Officer\nVictory Square Technologies Inc.\n\nAbout Canada's Top Growing Companies\n\nCanada's Top Growing Companies is an editorial ranking published by The Globe\nand Mail's Report on Business magazine. Launched in 2019, the voluntary\nprogram ranks qualifying Canadian businesses based on three-year revenue\ngrowth following an application and review process.\n\nThe 2026 ranking is available in the October issue of Report on Business\nmagazine and\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=3707409027&u=https%3A%2F%2Fwww.theglobeandmail.com%2Fbusiness%2Frob-magazine%2Ftop-growing-companies%2Farticle-ranking-canadas-top-growing-companies-of-2026%2F&a=%C2%A0)\nonline at The Globe and Mail\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=4184079136&u=https%3A%2F%2Fwww.theglobeandmail.com%2Fbusiness%2Frob-magazine%2Ftop-growing-companies%2Farticle-ranking-canadas-top-growing-companies-of-2026%2F&a=online+at+The+Globe+and+Mail)\n.\n\nAbout Victory Square Technologies Inc.\n\nVictory Square builds, acquires and invests in technology companies, providing\ncapital, strategic leadership and operational support to help them develop and\nscale. Its portfolio includes operating and development-stage businesses\nacross healthcare infrastructure, digital health, artificial intelligence, pet\nhealth and other emerging technology sectors.\n\nHeadquartered in Vancouver, Canada, Victory Square trades on the Canadian\nSecurities Exchange, the OTCQX market and the Frankfurt Stock Exchange.\n\nFor more information, visit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=2138118496&u=https%3A%2F%2Fvictorysquare.com%2F&a=%C2%A0)\nwww.victorysquare.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790333-1&h=2242282608&u=https%3A%2F%2Fvictorysquare.com%2F&a=www.victorysquare.com)\n.\n\nForward-Looking Information\n\nThis news release contains forward-looking information within the meaning of\napplicable securities laws, including statements concerning Victory Square's\nbusiness strategy, portfolio development, capital allocation, potential\nshareholder value, Insu Therapeutics' drug-delivery technology and potential\ncommercialization, Pawsible Ventures' development opportunities, and the\ntiming and content of the planned investor webinar.\n\nSuch information is based on management's current expectations and\nassumptions, including the availability of capital, demand for portfolio\ncompanies' products and services, successful research and development, receipt\nof applicable regulatory approvals and the ability to execute business plans.\nActual results may differ materially due to risks including market and\neconomic conditions, financing requirements, competition, regulatory changes,\nclinical and technological uncertainty, and operational execution. Additional\nrisks are described in the Company's public filings on SEDAR+.\n\nHistorical revenue growth and inclusion in an editorial ranking do not\nguarantee future operating results or investment returns. Readers should not\nplace undue reliance on forward-looking information. The Company undertakes no\nobligation to update such information except as required by applicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/victory-square-technologies-ranks-no-2-among-publicly-traded-companies-on-the-globe-and-mails-2026-canadas-top-growing-companies-list-302899250.html\n(https://www.prnewswire.com/news-releases/victory-square-technologies-ranks-no-2-among-publicly-traded-companies-on-the-globe-and-mails-2026-canadas-top-growing-companies-list-302899250.html)\n\nSOURCE Victory Square Technologies Inc\n\n\n\nir@victorysquare.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1830374/Victory-Square-Technologies-Inc-Victory-Square-Technologies-Rank.jpg?id=OA2988986\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-06T12:00:19.017133839Z","server_sent_at_ms":1791288019017},"received_at":"2026-10-06T12:00:19.068Z","source_url":"https://www.prnewswire.com/news-releases/victory-square-technologies-ranks-no-2-among-publicly-traded-companies-on-the-globe-and-mails-2026-canadas-top-growing-companies-list-302899250.html"},"analysis":{"id":"150287","press_release_id":"161769","analysis_json":{"industry":{"label":"Capital Markets","sector":"Financials"},"redFlags":["growth figures are company-reported and the ranking is a voluntary, application-based editorial program","portfolio mix is heavily dependent on a single subsidiary (Hydreight) for revenue","Insu remains pre-commercial pending clinical validation and regulatory approvals"],"eventType":"operations_update","narrative":"Victory Square Technologies ranked No. 58 overall on The Globe and Mail's 2026 Canada's Top Growing Companies list, with 497% three-year revenue growth — the second-highest among publicly traded companies ranked.\n\nThe company also restated previously announced H1 2026 results: consolidated revenue of CAD $53.0 million versus $9.9 million a year earlier (+434%), gross profit of $10.5 million, cash of $20.2 million and working capital of $34.5 million as of June 30, 2026.\n\nGrowth was primarily driven by Hydreight Technologies (TSXV: NURS), its U.S. digital health infrastructure subsidiary; Insu Therapeutics (peptide buccal delivery) and Pawsible Ventures (pet health) remain earlier-stage.\n\nManagement will host a corporate and portfolio update webinar on October 8, 2026, covering net asset value and capital allocation.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Promotional ranking release that repackages strong H1 2026 growth (+434% revenue) driven by Hydreight — note reliance on single subsidiary."},"keyFigures":{"revenue":"$53.0 million","revenueYoy":"434%","customDimensions":{"cash":"$20.2 million","gross_profit":"$10.5 million","ranking_overall":"No. 58","working_capital":"$34.5 million","h1_2025_revenue_cad":"$9.9 million","h1_2026_revenue_cad":"$53.0 million","three_year_revenue_growth":"497%","ranking_among_publicly_traded":"No. 2"}},"quotedText":"Behind this recognition are years of building, teams that kept executing and shareholders who supported us along the way","namedEntities":{"people":[{"name":"Shafin Diamond Tejani","role":"Chairman & CEO"}],"products":["Hydreight digital health platform","Insu buccal peptide delivery (incl. semaglutide)","Pawsible inaugural cohort (eight companies)"],"companies":[{"name":"Victory Square Technologies Inc.","ticker":"VST","relationship":"filer"},{"name":"Hydreight Technologies Inc.","ticker":"NURS","relationship":"majority-owned operating subsidiary and principal revenue driver"},{"name":"Insu Therapeutics","relationship":"development-stage subsidiary (peptide drug delivery)"},{"name":"Pawsible Ventures","relationship":"subsidiary pet-health venture platform"},{"name":"The Globe and Mail","relationship":"publisher of the ranking"}],"dollarAmounts":[{"amount":"$53.0 million","context":"H1 2026 consolidated revenue (CAD)"},{"amount":"$9.9 million","context":"H1 2025 consolidated revenue (CAD)"},{"amount":"$10.5 million","context":"H1 2026 consolidated gross profit (CAD)"},{"amount":"$20.2 million","context":"consolidated cash as at June 30, 2026 (CAD)"},{"amount":"$34.5 million","context":"consolidated working capital as at June 30, 2026 (CAD)"}]},"materialImpact":{"score":2,"reasoning":"Issuer-authored publicity release around a third-party editorial ranking, but it restates material H1 2026 figures (revenue +434% YoY, $20.2M cash). Recognition itself is non-binding promotional news; no new financial disclosure beyond previously announced results."},"tickerRelevance":{"others":[{"ticker":"NURS","relevance":"subsidiary"}],"primary":"VST"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap venture builder (CSE/OTCQX listed)","eventGravity":"editorial ranking recognition plus restated financials","issuerAuthored":true,"promotionalContent":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Victory Square Technologies ranked No. 58 overall on The Globe and Mail's 2026 Canada's Top Growing Companies list, with 497% three-year revenue growth — the second-highest among publicly traded companies ranked.\n\nThe company also restated previously announced H1 2026 results: consolidated revenue of CAD $53.0 million versus $9.9 million a year earlier (+434%), gross profit of $10.5 million, cash of $20.2 million and working capital of $34.5 million as of June 30, 2026.\n\nGrowth was primarily driven by Hydreight Technologies (TSXV: NURS), its U.S. digital health infrastructure subsidiary; Insu Therapeutics (peptide buccal delivery) and Pawsible Ventures (pet health) remain earlier-stage.\n\nManagement will host a corporate and portfolio update webinar on October 8, 2026, covering net asset value and capital allocation.","key_figures":{"revenue":"$53.0 million","revenueYoy":"434%","customDimensions":{"cash":"$20.2 million","gross_profit":"$10.5 million","ranking_overall":"No. 58","working_capital":"$34.5 million","h1_2025_revenue_cad":"$9.9 million","h1_2026_revenue_cad":"$53.0 million","three_year_revenue_growth":"497%","ranking_among_publicly_traded":"No. 2"}},"named_entities":{"people":[{"name":"Shafin Diamond Tejani","role":"Chairman & CEO"}],"products":["Hydreight digital health platform","Insu buccal peptide delivery (incl. semaglutide)","Pawsible inaugural cohort (eight companies)"],"companies":[{"name":"Victory Square Technologies Inc.","ticker":"VST","relationship":"filer"},{"name":"Hydreight Technologies Inc.","ticker":"NURS","relationship":"majority-owned operating subsidiary and principal revenue driver"},{"name":"Insu Therapeutics","relationship":"development-stage subsidiary (peptide drug delivery)"},{"name":"Pawsible Ventures","relationship":"subsidiary pet-health venture platform"},{"name":"The Globe and Mail","relationship":"publisher of the ranking"}],"dollarAmounts":[{"amount":"$53.0 million","context":"H1 2026 consolidated revenue (CAD)"},{"amount":"$9.9 million","context":"H1 2025 consolidated revenue (CAD)"},{"amount":"$10.5 million","context":"H1 2026 consolidated gross profit (CAD)"},{"amount":"$20.2 million","context":"consolidated cash as at June 30, 2026 (CAD)"},{"amount":"$34.5 million","context":"consolidated working capital as at June 30, 2026 (CAD)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T12:00:45.314Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"micro-cap venture builder (CSE/OTCQX listed)","eventGravity":"editorial ranking recognition plus restated financials","issuerAuthored":true,"promotionalContent":true}},"durationMs":7850,"modelName":"glm-5.3-flashx"}}